Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
7 Odd Apparatuses to Make Your Party Stick Out! - 2Solar storms have influenced our history – an environmental historian explains how they could also threaten our future
- 3\Step by step instructions to Pick the Best Material Organization for Your Home\
- 4Reports: Germany plans expansion of foreign intelligence powers
- 5As tetanus vaccination rates decline, doctors worry about rising case numbers
- French and Malaysian authorities are investigating Grok for generating sexualized deepfakes
- Flu concerns grow in US as UK sees more cases among kids
- Building an Individual Brand: Illustrations from Powerhouses
- Vote In favor of Your Favored Shades
- Figure out How to Protect Your Gold Venture from Unpredictability
- If evolution is real, then why isn’t it happening now? An anthropologist explains that humans actually are still evolving
- The 12 biggest space stories of 2025 — according to you
- Picking the Right Doctor prescribed Medication Inclusion in Senior Protection.
- Fascinating Fishing Objections From Around The World
